Leptomeningeal metastasis, also known as malignant meningitis and referred to as “Lepto” or “LMD” amongst oncologists, is a life-threatening complication of cancers which have spread to the meningeal lining of the brain and spinal cord. LMD can come from cancers arising in the brain or elsewhere in the body and is relatively uncommon, arising in 3 to 5% of patients with common metastatic malignancies like lung cancer, breast cancer, and melanoma.
CLIA Certification Broadens Cellworks’ Capabilities to Deliver Personalized Therapy Predictions that Improve Cancer Treatment Outcomes
Study Introduces a Personalized Method of Predicting Immunotherapy Response in NSCLC Patients and Reveals Specific Immune Markers Correlated with Improved Outcomes
Data from a small clinical trial of venetoclax in acute myeloid leukemia (AML) supported an FDA breakthrough therapy designation for use in combination with hypomethylating agents in treatment-naïve patients who are ineligible for high-dose induction chemotherapy (PMID: 31628431). Approval of BCL-2 inhibitors raises the question of the mechanism of action in AML and patient selection for treatment. Unfortunately, no biomarkers or methods exist to predict venetoclax response in AML, making treatment selection challenging.
Study finds utilizing genomic and transcriptomic data with biosimulation enhances personalized predictions of IO response in NSCLC
Personalized Therapy Biosimulation Study Identifies Homologous Recombination Deficiency in Cancer Patients Beyond BRCA Status
New study validates Cellworks predictions of chemotherapy benefits in real-world NSCLC patients, guiding treatment decisions beyond PD-L1 status
Study Uncovers Biomarkers Linked to Chemotherapy Response in NSCLC Patients Carrying EGFR Variants